Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance

BM Hougardy, JH Maduro, AGJ van der Zee, PHB Willemse, S de Jong, EGE de Vries*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

36 Citations (Scopus)

Abstract

Cervical cancer is the most common gynaecological malignant disorder worldwide. The best possible treatment of locally advanced cervical cancer is a combination of radiation and cisplatin-based chemotherapy. However, 5-year overall survival is still only 52%. To improve treatment results, research should focus on the discovery of innovative drug strategies. Drugs directed at inducing tumour-cell apoptosis are regarded as important treatment modalities. Here, we present an overview of the molecular options that can change the apoptotic balance in cervical cancer, through increasing death-receptor-mediated apoptosis, the use of proteasome inhibitors, short interfering RNAs, or non-steroidal anti-inflammatory drugs (NSAIDs). Furthermore, the potential of attacking prosurvival signalling through the epidermal-growth-factor receptor and insulin-like-growth-factor receptor to support the apoptotic process is discussed. Additional research is needed to elucidate the clinical potential of these compounds in the treatment of cervical cancer.

Original languageEnglish
Pages (from-to)589-598
Number of pages10
JournalLancet Oncology
Volume6
Issue number8
Publication statusPublished - Aug-2005

Keywords

  • GROWTH-FACTOR-RECEPTOR
  • SQUAMOUS-CELL CARCINOMA
  • NF-KAPPA-B
  • HUMAN-PAPILLOMAVIRUS TYPE
  • IGF-BINDING PROTEIN-3
  • FACTOR-I RECEPTOR
  • UTERINE CERVIX
  • HUMAN KERATINOCYTES
  • TRAIL-RESISTANCE
  • RNA INTERFERENCE

Cite this